Objective: Hemifacial spasm (HFS) is a common movement disorder characterized by involuntary contractions of the muscles innervated by facial nerve.

Background: To evaluate the effect and safety of incobotulinumtoxinA (INCO) in the treatment of HFS

Method: A retrospective analysis of patients treated in Neurology Outpatient Clinic from 2015 to 2018 was carried out. Clinical Global Impression scale (CGI), and percent of improvement were used for access clinical improvement. The quality of life was measured with self rating scale (HFS-7).

Results: A total of 540 INCO injections were administered to 45 HFS patients. The mean initial dose was 28.5 units, the mean dose for subsequent injections was 57.2 units. Patients were evaluated at 4 weeks after injection, and in intervals of 12 weeks after each application. Mean duration of improvement following each injection sessions was 14.3 weeks, mean latency to detection improvement was 5.7 days, the mean success rate was 74.7 %. The QoL improvement was statistically significant. Adverse effects, which were mostly minor, were observed in 18 % of the patients at least once during follow-up. The most frequent was ptosis 8,4%, and subcutaneous haematoma 3.5%.

Conclusion: Treatment of HFS with INCO was effective, sustainable and safe, improve QoL, and had minimal, well tolerated side effects.

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/incobotulinumtoxina-is-effective-long-lasting-and-well-tolerated-treatment-of-hemifacial-spasm/